Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Servier
M.D. Anderson Cancer Center
Eli Lilly and Company
M.D. Anderson Cancer Center
Instituto do Cancer do Estado de São Paulo
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Turning Point Therapeutics, Inc.
Eastern Cooperative Oncology Group
Sotio Biotech Inc.
Erasca, Inc.
Kaiser Permanente
Sichuan Enray Pharmaceutical Sciences Company
Arvinas Inc.
Jonsson Comprehensive Cancer Center
University of Colorado, Denver
Fred Hutchinson Cancer Center
Eli Lilly and Company
RenJi Hospital
Degron Therapeutics Co.
National Cancer Institute (NCI)
Bayer
UNC Lineberger Comprehensive Cancer Center
Actym Therapeutics, Inc.
Merck Sharp & Dohme LLC
Ikena Oncology
Washington University School of Medicine
Sensei Biotherapeutics, Inc.
Jonsson Comprehensive Cancer Center
Sichuan Enray Pharmaceutical Sciences Company
Apollomics Inc.
ModeX Therapeutics, An OPKO Health Company
University of Alabama at Birmingham
TransThera Sciences (Nanjing), Inc.
Hoffmann-La Roche
Columbia University
Xynomic Pharmaceuticals, Inc.
SOLTI Breast Cancer Research Group
Cedars-Sinai Medical Center
National Cancer Institute (NCI)
Rutgers, The State University of New Jersey
Universidade Federal de Pernambuco
Salubris Biotherapeutics Inc
NantCell, Inc.
ABM Therapeutics Corporation
TransThera Sciences (Nanjing), Inc.
Istituti Clinici Scientifici Maugeri SpA
M.D. Anderson Cancer Center